Massachusetts-based Ring Therapeutics has partnered with Singapore’s A*STAR and SERI to advance gene therapy using its ...

Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & ...

French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO) ...

The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an ...

Disc Medicine today announced a successful End of Phase 2 with the US Food and Drug Administration (FDA) supporting the ...

US biopharma Kymera Therapeutics, which is developing a new class of small molecule medicines using targeted protein degradation (TPD), has announced an important update on its pipeline.

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...